The epigenetic modifier lysine methyltransferase 2C is frequently mutated in gastric remnant carcinoma
The Journal of Pathology: Clinical Research · 2023-09 · 9 (5) · 409-422
DOI: 10.1002/cjp2.335 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 03.07.2023. Verfasst von Bo Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, PR China. Hauptthemen laut MEDLINE: Gastric Stump, Carcinoma, Stomach Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Gastric remnant carcinoma (GRC), which occurs in the stomach after partial gastrectomy, is a rare and aggressive form of gastric adenocarcinoma (GAC). Comprehensive profiling of genomic mutations in GRC could provide the basis for elucidating the origin and characteristics of this cancer. Herein, whole‐exome sequencing (WES) was performed on 36 matched tumor–normal samples from patients with GRC and identified recurrent mutations in epigenetic modifiers, notably KMT2C , ARID1A , NSD1 , and KMT2D , in 61.11% of cases. Mutational signature analysis revealed a low frequency of microsatellite instability (MSI) in GRC, which was further identified by MSIsensor, MSI‐polymerase chain reaction, and immunohistochemistry analysis. Comparative analysis demonstrated that GRC had a distinct mutation spectrum compared to that of GAC in The Cancer Genome Atlas samples, with a significantly higher mutation rate of KMT2C . Targeted deep sequencing (Target‐seq) of an additional 25 paired tumor–normal samples verified the high mutation frequency (48%) of KMT2C in GRC. KMT2C mutations correlated with poor overall survival in both WES and Target‐seq cohorts and were independent prognosticators in GRC. In addition, KMT2C mutations were positively correlated with favorable outcomes in immune checkpoint inhibitor‐treated pan‐cancer patients and associated with higher intratumoral CD3 + , CD8 + tumor‐infiltrating lymphocyte counts, and PD–L1 expression in GRC samples ( p = 0.018, 0.092, 0.047, 0.010, and 0.034, respectively). Our dataset provides a platform for information and knowledge mining of the genomic characteristics of GRC and helps to frame new therapeutic approaches for this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, PR China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China.
- CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, PR China.
- Department of Gastric Surgery, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, PR China.
ORCID-Profile: Bo Sun
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, B., Chen, H., Lao, J., Tan, C., Zhang, Y., Shao, Z., & Xu, D. (2023). The epigenetic modifier lysine methyltransferase 2C is frequently mutated in gastric remnant carcinoma. The Journal of Pathology: Clinical Research, 9(5), 409-422. https://doi.org/10.1002/cjp2.335
Vancouver
Sun B, Chen H, Lao J, Tan C, Zhang Y, Shao Z, et al. The epigenetic modifier lysine methyltransferase 2C is frequently mutated in gastric remnant carcinoma. The Journal of Pathology: Clinical Research. 2023;9(5):409-422. doi:10.1002/cjp2.335
BibTeX
@article{Sun2023,
author = {Sun, Bo and Chen, Haojie and Lao, Jiawen and Tan, Cong and Zhang, Yue and Shao, Zhen and Xu, Dazhi},
title = {The epigenetic modifier lysine methyltransferase 2C is frequently mutated in gastric remnant carcinoma},
journal = {The Journal of Pathology: Clinical Research},
year = {2023},
volume = {9},
number = {5},
pages = {409--422},
doi = {10.1002/cjp2.335}
}
EUVIMED